Brookline analyst Kemp Doliver downgraded Apexigen to Hold from Buy.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on APGN:
- Apexigen downgraded to Neutral from Buy at Roth MKM
- Apexigen announces review of strategic alternatives, 55% workforce reduction
- Apexigen Announces Approximately $2.8 Million Private Placement Financing
- Apexigen announces $2.8M private placement financing
- Apexigen resumed with a Buy at Roth Capital
Questions or Comments about the article? Write to editor@tipranks.com